Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $142.64, for a total transaction of $99,848.00. Following the completion of the transaction, the vice president now directly owns 27,772 shares of the company’s stock, valued at approximately $3,961,398.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of NYSE:EW opened at $148.63 on Thursday. The firm has a market cap of $36.45 billion, a price-to-earnings ratio of 39.11, a P/E/G ratio of 2.41 and a beta of 0.56. Edwards Lifesciences Corp has a 12-month low of $100.20 and a 12-month high of $175.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47.
Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company had revenue of $972.00 million during the quarter, compared to analyst estimates of $968.32 million. During the same quarter last year, the business posted $1.08 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. Equities analysts forecast that Edwards Lifesciences Corp will post 4.67 EPS for the current fiscal year.
A number of equities analysts recently commented on EW shares. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Saturday, July 14th. Guggenheim reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $168.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. SunTrust Banks decreased their price objective on shares of Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a research note on Friday, August 10th. Finally, ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. Two analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company’s stock. Edwards Lifesciences has a consensus rating of “Buy” and a consensus price target of $154.70.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Further Reading: What strategies should day traders use to execute a trade?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.